San Francisco-based Multiply Labs raised a Series B of USD 75 million, and the company said it will use the proceeds to expand manufacturing capacity, accelerate its product roadmap, and scale its engineering, regulatory, and commercial teams as it builds the operational foundation for the transition from clinical-stage deployments to commercial-scale production.
The round was led by Dr. Patrick Soon-Shiong with NantWorks, with new investors AstraZeneca, Lingotto, Teradyne, and Strange Ventures joining returning backers Casdin Capital, Lux Capital, Fifty Years, Ora Global, and Founders Fund, among others. According to the company's release, the financing brings total capital raised since its 2016 founding to over 100 million dollars.
Multiply Labs' core offering is a robotic-cluster platform that automates timed, repetitive steps in biologics manufacturing within enclosed, good manufacturing practice (GMP)-compliant systems, designed to integrate with existing instruments and processes without requiring new facilities or changes to validated workflows. The company reports the system delivers a 74% reduction in cost per dose and up to 100 times more throughput than manual manufacturing. Initially focused on cell and gene therapy, the platform is expanding into antibodies, viral vectors, and mRNA. Each cluster is owned and operated by the pharmaceutical company itself, keeping production, data, and supply chain in-house.
The platform supports material external relationships: Multiply Labs has an agreement with AstraZeneca to evaluate GMP-ready robotic systems for commercial-scale cell-therapy manufacturing, and a collaboration with GenScript Biotech to automate the cell-isolation and enrichment phase of cell-therapy manufacturing.